A Day of Reckoning for Aging Facilities: Is It Time to Invest in Change?
This article was originally published in Scrip
With its acquisition of Hospira, Pfizer joins the ranks of pharmaceutical companies struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades for fear of triggering additional drug shortages. Meanwhile, flexible, modular next-generation facilities that could add capacity where needed are on the horizon.
You may also be interested in...
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.
Draft recommendation offers path to ICH Q12 regulatory relief.
Accelerating post-approval change oversight by focusing on ‘established conditions’ means trusting pharmaceutical quality management systems. But how?